Delphia Therapeutics
Rebecca (Becky) Lock, PhD, currently serves as Director at Delphia Therapeutics since August 2024. Prior to this, Lock held various positions at Arrakis Therapeutics from April 2019 to March 2024, progressing from Scientist to Associate Director of Discovery Biology, where leadership was demonstrated in the development of a novel small molecule inhibitor of MYC and overseeing cross-functional teams. Previous experience includes a postdoctoral research fellowship at Brigham and Women's Hospital from February 2012 to March 2019, focusing on therapeutic combinations in cancer, and a role as a graduate student at UCSF from 2005 to 2011, studying autophagy in cancer biology. Educational qualifications include a Ph.D. in Oncology and Cancer Biology from UCSF and a B.S. in Biochemistry/Biophysics from Rensselaer Polytechnic Institute.
This person is not in any teams
Delphia Therapeutics
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.